Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 31;13(12):6608-6612.
doi: 10.21037/tcr-24-1755. Epub 2024 Dec 25.

Targeting the EZH2-SLFN11 pathway-a lesson in developing molecularly-informed treatments for recurrent small cell lung cancer

Fangdi Sun  1 , Millie S Das  1   2
Affiliations
Editorial

Targeting the EZH2-SLFN11 pathway-a lesson in developing molecularly-informed treatments for recurrent small cell lung cancer

Fangdi Sun et al. Transl Cancer Res. .
No abstract available

Keywords: Schlafen family member 11 (SLFN11); Small cell lung cancer (SCLC); enhancer of zeste homolog 2 (EZH2); irinotecan.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-1755/coif). F.S. has participated in an advisory board for OncoHost and received honoraria from MJH Life Sciences. M.S.D. has received honoraria from Plexus Communications, IDEO Health, Springer, Medical Educator Consortium, Dedham Group, DAVA Oncology, MJH Life Sciences, Targeted Oncology, OncLive, Association of Northern California Oncologists, Aptitude Health, MashUp Media, Curio Science, Med Learning Group, Triptych Health, and American Cancer Society; has participated in an advisory board for Advarra; has served as a consultant for Sanofi/Genzyme, Regeneron, Catalyst Pharmaceuticals, Novocure, Guardant, EMD Soreno, Janssen, Abbvie, Gilead, Daiichi Sankyo, and Bristol Myers Squibb; and has received institutional research funding from Merck, Genentech, CellSight, Novartis, and Varian. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Wang Q, Gümüş ZH, Colarossi C, et al. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J Thorac Oncol 2023;18:31-46. 10.1016/j.jtho.2022.10.002 - DOI - PMC - PubMed
    1. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929-39. 10.1016/S0140-6736(19)32222-6 - DOI - PubMed
    1. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018;379:2220-9. 10.1056/NEJMoa1809064 - DOI - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer V.2.2025. National Comprehensive Cancer Network, Inc. 2024. - PubMed
    1. Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol 2021;32:839-53. 10.1016/j.annonc.2021.03.207 - DOI - PMC - PubMed

LinkOut - more resources